JP7159511B1 - Composition for skin improvement - Google Patents

Abstract

An object of the present disclosure is to provide at least a technique for improving skin, and the object is solved by a skin-improving composition containing isoflavone-based glycosides and/or isoflavone-based aglycones and lactobionic acid. .

Description

The present disclosure relates to skin improving compositions.

It has been known for a long time that isoflavones (especially aglycones of isoflavones such as genistein and daidzein) promote hyaluronic acid production in the skin, improve collagen metabolism, and have the effect of alleviating rough skin (patent literature 1). For example, a clinical trial conducted on 26 women in their 30s and 40s reported that oral intake of 40 mg of isoflavone aglycones per day for 3 months promoted the production of collagen and reduced the wrinkle area (non Patent document 1).
On the other hand, lactobionic acid (4-O-β-galactopyranosyl-D-gluconic acid) is an acidic oligosaccharide obtained by oxidizing lactose. Are known. Lactobionic acid is expected to stabilize the lamellar structure responsible for the moisturizing function in the skin structure, and to have a moisturizing effect and a skin protecting effect (Non-Patent Document 2). It has also been reported that administration of calcium lactobionate to rats significantly increases the plasma equol concentration (Patent Document 2).
However, it is not known that when lactobionic acid and glycosides of isoflavones and/or aglycones of isoflavones are used in combination, the skin is more improved than when each of them is ingested alone.

JP 2001-335454 A Japanese Patent Application Laid-Open No. 2008-1608

J. Nutr. Sci. Vitaminol., 53, 57-62 (2007) Wakasa secret, lactobionic acid, [online], Wakasa life, [searched on June 29, 2020], Internet <URL: http://www.wakasanohimitsu.jp/seibun/lactobionic-acid/>

An object of the present disclosure is to provide at least a technique for improving skin.

The present inventors have found that the above problems can be solved by ingesting isoflavone glycosides and/or isoflavone aglycones in combination with lactobionic acid.
The present disclosure can provide a skin-improving composition comprising an isoflavone glycoside and/or an isoflavone aglycone and lactobionic acid.
In the composition, the total daily intake of the isoflavone glycosides and/or isoflavone aglycones is 20 mg or more and less than 30 mg in terms of aglycone, and the daily intake of the lactobionic acid is A preferable aspect is that the content is 200 mg or more.
The composition is also preferably a food or drink.

INDUSTRIAL APPLICABILITY The present disclosure can have the effect of providing at least a technique for improving skin.

2 is a graph showing the relationship between the time after ingestion and the amount of change in stratum corneum water content in Example 2 according to one aspect of the present disclosure, where (a) is for the left cheek and (b) is for the left shin. is a graph of 10 is a graph showing the relationship between the time after ingestion and the amount of change in transepidermal water loss (TEWL) in Example 2 according to one aspect of the present disclosure. 2 is a graph showing the relationship between the time after ingestion and the amount of change in skin viscoelasticity in Example 2 according to one aspect of the present disclosure, where (a) is net elasticity (R5) and (b) is gross body elasticity (R2 ) shows the results. 2 is a graph showing the relationship between the time after ingestion and the amount of change in skin viscoelasticity in Example 2 according to one aspect of the present disclosure, where (a) is the return rate (R7) and (b) is the unrecovered extensibility/ Results for retraction capacity (R1) are shown. 10 is a graph showing the relationship between the time after ingestion and the amount of change in the score of the item “sagging under the eyes” in the skin condition questionnaire in Example 2 according to one aspect of the present disclosure.

One aspect of the present disclosure is a skin-improving composition comprising an isoflavone glycoside and/or an isoflavone aglycone and lactobionic acid. In the present disclosure, the composition may be referred to as "the composition according to this aspect" and the like.

The composition according to this aspect may contain only isoflavone glycosides and/or isoflavone aglycones and lactobionic acid, or may contain other ingredients as long as the skin is improved in a subject ingesting it. may contain ingredients.

A subject who ingests the composition according to this aspect is a human, preferably a human who seeks improvement of the skin. The human may be male or female.

In this aspect, the improvement in the skin means that the subject is better than when the subject is not ingesting the isoflavone glycoside and/or the isoflavone aglycon and lactobionic acid (or when the placebo is ingested). It is said that the combined intake of glycosides and/or aglycones of isoflavones and lactobionic acid improves the skin.

Skin improvement includes, for example, improvement of stratum corneum moisture content (e.g., suppression of decrease or increase of stratum corneum moisture content), and improvement of skin caused by improvement of stratum corneum moisture content includes, for example, skin moisturizing properties. , improvement of flexibility, improvement of texture, improvement of skin barrier function, and improvement of wrinkles. The stratum corneum moisture content can be measured, for example, by measuring the capacitance of the skin surface using Corneometer (registered trademark) CM825 (Courage+Khazaka electronic GmbH).

In addition, skin improvement includes, for example, improvement of transepidermal water loss (TEWL) (e.g., suppression of increase or decrease of TEWL), and skin improvement resulting from improvement of TEWL includes: For example, improvement of skin moisturizing properties, improvement of flexibility, improvement of skin texture, improvement of skin barrier function, and improvement of wrinkles can be mentioned. Transepidermal water loss (TEWL) is measured using, for example, a Tewameter® TM300 (Courage+Khazaka electronic GmbH) through two sets of sensitive temperature and humidity sensors placed at the tip of the probe. It can be done by measuring the temperature difference and humidity difference of the moisture.

Skin improvement includes, for example, improvement in skin viscoelasticity, and skin improvement resulting from improvement in skin viscoelasticity includes, for example, improvement in skin flexibility. Improvement of skin viscoelasticity can be judged by focusing on, for example, net elasticity (R5), total body elasticity (R2), return rate (R7), unrecovered extensibility/retraction ability (R1), and the like. Since net elasticity (R5), total body elasticity (R2), and return rate (R7) are values that decrease with age, it is judged that improvement was achieved by suppressing the decrease in value and increasing the value. be able to. On the other hand, since the unrecovered extensibility/retraction capacity (R1) is a value that increases with age, it can be determined that the increase in the value is suppressed or the value is decreased, thereby improving. Skin viscoelasticity measurements can be performed, for example, using a Cutometer® MPA580 (Courage+Khazaka electronic GmbH, probe diameter 2 mm).

In addition, as skin improvement, for example, improvement of worrisome pores, improvement of rough texture, improvement of rough skin, improvement of worrisome spots and freckles , Poor complexion is improved, lack of transparency in the skin is improved, dullness of the skin is improved, dryness of the skin is improved, fine wrinkles at the corners of the eyes are worrisome improvement, improvement in sagging under the eyes, improvement in lack of firmness and luster, improvement in lack of plumpness in the skin, improvement in the tendency for makeup to come off, poor makeup application Improvement of poor skin condition, improvement of greasy face, improvement of acne proneness, improvement of itchy skin (skin itching) to do. These can be determined based on the results of skin condition questionnaires conducted by panelists who have been trained to be able to make objective evaluations, for example.

Isoflavones are one of polyphenols, and are flavonoids having isoflavone as a basic skeleton. In general, isoflavones broadly refer to flavonoids having isoflavone as a basic skeleton. The isoflavones of the present disclosure are also defined as such.
Isoflavones are contained in leguminous plants such as soybean, arrowroot, red clover, and licorice. The isoflavones in the present embodiment include, for example, isoflavones derived from leguminous plants containing isoflavones. isoflavones”, etc., and are treated as synonymous in the present disclosure.), isoflavones derived from kudzu (in the relevant technical field and market, they are referred to as “kudzu isoflavones”, “kudzu isoflavones”, etc. are treated as synonymous in the present disclosure), red clover-derived isoflavones (sometimes referred to in the art and in the market as “red clover isoflavones” or “red clover isoflavones”, and in the present disclosure are treated as synonyms.), isoflavones derived from licorice (sometimes referred to as “licorice isoflavones” or “licorice isoflavones” in the technical field and market, and treated as synonyms in the present disclosure).

Examples of the isoflavone glycosides include genistin, glycitin, daidzin, and puerarin, and the composition according to this embodiment may be a mixture of two or more of them. For example, it may be a mixture of daidzin, glycitin, and genistin.

Examples of aglycones of isoflavones include daidzein, 6-hydroxydaidzein, dihydroxydaidzein, genistein, glycitein, biochanin A, formonetin, and coumestrol. may be a mixture of The aglycone of isoflavones may be converted from isoflavones by an enzyme such as β-glucosidase or a microorganism having β-glucosidase. The term "aglycones of isoflavones" in the present disclosure is sometimes referred to as "isoflavone aglycones" in the technical field and market, and is treated as synonymous in the present disclosure.

Lactobionic acid is a disaccharide and sugar acid composed of gluconic acid and galactose. Lactobionic acid is sometimes described as 4-O-β-galactopyranosyl-D-gluconic acid.
Lactobionic acid is produced by allowing microorganisms with lactose-oxidizing activity, such as Acinetobacter, Burkholderia, Acetobacter, and Gluconobacter, to act on the raw material, lactose, to oxidize the lactose and produce the supernatant. It is known to be obtained by collecting. Details are described in JP-A-2001-245657, JP-A-2007-28917, and the like.

The total content of isoflavone glycosides and/or isoflavone aglycones with respect to the total amount of the composition according to this embodiment is preferably 0.001% by weight or more, more preferably 0.01% by weight or more. more preferably 0.1% by weight or more, on the other hand, preferably 50% by weight or less, more preferably 40% by weight or less, and even more preferably 10% by weight or less. Also, a non-contradictory combination thereof may be used.

The content of lactobionic acid relative to the total amount of the composition according to this aspect is preferably 0.01% by weight or more, more preferably 0.1% by weight or more, and still more preferably 1% by weight or more, while , preferably 99.9% by weight or less, more preferably 80% by weight or less, and even more preferably 60% by weight or less. Also, a non-contradictory combination thereof may be used.

The intake of isoflavone glycosides and/or isoflavone aglycones and lactobionic acid in the composition according to this aspect depends on the age and body weight of the subject, as well as diseases, disorders, symptoms, and symptoms (herein, " Diseases, disorders, symptoms, symptoms" may be collectively referred to as "disease, etc."), route of intake, intake schedule, formulation form, etc. When the aglycones of isoflavones and lactobionic acid are used in combination, the skin is improved more than the glycosides of the isoflavones and/or the aglycones of the isoflavones alone and the lactobionic acid alone in the subject who has ingested it. Not limited.

The total intake of isoflavone glycosides and/or isoflavone aglycones is preferably 20 mg or more, more preferably 25 mg or more per day in terms of aglycone. On the other hand, for example less than 30 mg. Also, a non-contradictory combination thereof may be used.
Regarding aglycone conversion, for example, with regard to isoflavone glycosides, the form from which the glycoside is eliminated is the aglycone of isoflavones. It is possible to calculate the intake amount when converted to the aglycon of In addition, the total amount of isoflavone aglycones can be treated as the intake of isoflavone aglycones.

In addition, the total intake of lactobionic acid is preferably 200 mg or more, more preferably 225 mg or more, and still more preferably 250 mg or more per day, while preferably 1,000 mg or less, more preferably 800 mg or less, More preferably, it is 500 mg or less. Also, a non-contradictory combination thereof may be used.

The total intake ratio of isoflavone glycosides and/or isoflavone aglycones to lactobionic acid is preferably 1:2 to 40, more preferably 1:2 to 10, and further Preferably, it is 1:2-5.

According to the guideline of the Ministry of Health, Labor and Welfare, the daily intake of soy isoflavone aglycones (aglycones of isoflavones derived from soybeans) is stipulated not to exceed 30 mg. From this point of view as well, the total intake of isoflavone glycosides and/or isoflavone aglycones is preferably less than 30 mg per day in terms of isoflavone aglycones. The fact that skin is improved by ingesting isoflavones glycosides and/or isoflavones aglycones in a total amount of less than 30 mg per day in terms of isoflavones aglycones in a mode that does not contain an active ingredient such as lactobionic acid. unknown.

Moreover, the intake schedule of the composition according to this aspect may be one intake per day, or may be divided into multiple intakes per day. Also, it may be ingested once every several days or several weeks, but it is preferably ingested every day. In addition, the intake period may be, for example, 4 weeks or more, 8 weeks or more, or 12 weeks or more, or may be 12 weeks or less, 8 weeks or less, or 4 weeks or less, in a consistent combination thereof. There may be. It is preferably 4 weeks or more, more preferably 8 weeks or more, and still more preferably 12 weeks or more, while the upper limit is not particularly limited. may Also, for example, 4 to 12 weeks, 4 to 8 weeks, 4 to 4 weeks (i.e. 4 weeks), 8 to 12 weeks, 8 to 8 weeks (i.e. 8 weeks), 12 It may be more than one week and less than 12 weeks (that is, 12), and so on.

The composition according to this aspect can be used as food and drink (including supplements). For example, it can be used as a skin-improving food or drink containing isoflavone glycosides and/or isoflavone aglycones and lactobionic acid. Moreover, you may utilize for uses, such as "cosmetics to eat" and "cosmetics to eat."

When glycosides of isoflavones and/or aglycones of isoflavones and lactobionic acid are used as raw materials for food and drink, they can be used as foods for specified health uses, nutritional supplements, functional foods, and foods for the sick, in addition to general food and beverages. , food additives, etc. (including beverages). The form of the food and drink may be a form other than the plant itself or the animal itself containing isoflavone glycosides and/or isoflavone aglycones and lactobionic acid. It may be molded into edible forms such as granules, granules, tablets, capsules, pastes, etc., and various foods such as ham, sausage, etc. Meat processing It can be used by adding to foods, fishery processed foods such as fish cakes and chikuwa, breads, sweets, butter, milk powder and fermented dairy products, and can be used by adding to beverages such as water, fruit juice, milk and soft drinks. .

The above-mentioned food and drink can contain water, proteins, carbohydrates, lipids, vitamins, minerals, organic acids, organic bases, fruit juices, flavors and the like as main ingredients. Examples of proteins include animal and plant proteins such as whole milk powder, skim milk powder, partially skim milk powder, casein, soybean protein, chicken egg protein and meat protein, hydrolysates thereof, and butter. Carbohydrates include saccharides, processed starch (dextrin, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber, and the like. Lipids include, for example, vegetable oils such as lard, safflower oil, corn oil, rapeseed oil, coconut oil, fractionated oils thereof, hydrogenated oils, and transesterified oils. Examples of vitamins include vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline. , folic acid, etc. Minerals include, for example, calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, selenium, and whey minerals. Organic acids include, for example, malic acid, citric acid, lactic acid, and tartaric acid. These ingredients may be used in combination of two or more, and synthetic products and/or food and drink products containing these in large amounts may be used.

The above-mentioned food and drink can be produced according to a conventional method. In addition, the amount of isoflavone glycoside and/or isoflavone aglycone and lactobionic acid to be added to food or drink, the method of blending, and the timing of blending can be appropriately selected. Furthermore, if necessary, it can be enclosed in an appropriate container such as a bottle, bag, can, box, pack, or the like.

Regarding the content of isoflavone glycosides and/or isoflavone aglycone and lactobionic acid relative to the total amount of the food and drink, the intake amount of the food and drink, and the intake schedule of the food and drink, the total amount of the composition according to the present embodiment is Descriptions of the content of isoflavone glycosides and/or isoflavone aglycones and lactobionic acid, the intake amount of the composition according to this embodiment, and the intake schedule of the composition according to this embodiment are incorporated herein.

When glycosides of isoflavones and/or aglycones of isoflavones and lactobionic acid are used as raw materials for food and drink and used for improving skin, the use may be described as food and drink, and the use may be recalled from the use. It may be a food or drink that describes the intended use.
Improvement of skin moisturizing property and improvement of skin barrier function are, for example, to retain skin moisture, protect skin moisture, prevent skin moisture from escaping, prevent skin from drying out, relieve dryness, and improve skin moisture. It can be described as maintaining moisture, enhancing the barrier function of the skin, enhancing moisturizing power, and the like.
Improvement of skin flexibility can be described as, for example, alleviating or suppressing a decrease in skin elasticity, or maintaining skin elasticity.
The improvement of texture can be described as, for example, adjusting the texture of the skin, suppressing the deterioration of the texture, and making the texture finer.
Improvement of wrinkles can be described as, for example, removing wrinkles, eliminating wrinkles, making the skin plump, softening wrinkles, preventing wrinkles from settling, and eliminating aging.
The improvement of pores can be described as, for example, improving the opening of pores, tightening pores, improving the conspicuousness of pores, and the like.

The isoflavone glycoside and/or isoflavone aglycone contained in the composition according to this aspect may be a composition containing isoflavone glycoside and/or isoflavone aglycone. Soybean germ extracts containing aglycones of glycosides and/or isoflavones can be mentioned.
Therefore, the composition according to this aspect may be a skin-improving composition containing a composition containing an isoflavone glycoside and/or an isoflavone aglycone and lactobionic acid. In addition, the composition according to this aspect may be a skin-improving composition containing a soybean germ extract containing isoflavone glycosides and/or isoflavone aglycones and lactobionic acid.
Preferably, the isoflavone glycoside is a mixture of daidzin, glycitin and genistin. Also, the aglycone of said isoflavones is a mixture of daidzein, glycitein and genistein.

The soybean germ extract containing the isoflavone glycosides and/or isoflavone aglycones can be extracted from soybeans and soybean germ (hypocotyl). Water, ethanol, or hydrous ethanol can be used for the extraction. Further, for example, it can be obtained as in the document "Development of plant polyphenol-containing materials - their functionality and safety -" (published in 2007, CMC Publishing Co., Ltd.), and as in the examples described later. Obtainable.
In addition, if the soybean germ extract containing isoflavone glycosides and/or isoflavone aglycones contains isoflavone glycosides and/or isoflavone aglycones, the components are extracted or purified. may have been

The soybean germ extract containing isoflavone glycosides and/or isoflavone aglycones can be used as a solid by heat drying, spray drying, or freeze drying, if necessary. Both the heat drying treatment and the spray drying treatment can be performed using, for example, a spray drying apparatus. The freeze-drying process can be performed using a freeze-drying apparatus. Further, after the heat drying treatment, spray drying treatment, or freeze drying treatment, powdering treatment may be performed as necessary.

The lactobionic acid contained in the composition according to this aspect may be a composition containing lactobionic acid, such as a fermented product containing lactobionic acid.
Therefore, the composition according to this aspect may be a skin-improving composition containing a composition containing an isoflavone glycoside and/or an isoflavone aglycone and lactobionic acid. In addition, the composition according to this aspect may be a skin-improving composition containing isoflavone glycosides and/or isoflavone aglycones and a fermented product containing lactobionic acid.

The fermented product can be obtained by the method described above.

If necessary, the fermented product containing lactobionic acid can be used after being solidified by heat drying, spray drying, or freeze drying. Both the heat drying treatment and the spray drying treatment can be performed using, for example, a spray drying apparatus. The freeze-drying process can be performed using a freeze-drying apparatus. Further, after the heat drying treatment, spray drying treatment, or freeze drying treatment, powdering treatment may be performed as necessary.

As described above, the composition according to this aspect may be a skin-improving composition containing a composition containing an isoflavone glycoside and/or an isoflavone aglycone and a composition containing lactobionic acid. Further, the composition according to this aspect may be a skin-improving composition containing a soybean germ extract containing isoflavone glycosides and/or isoflavone aglycones and a fermented product containing lactobionic acid.

In addition, the present disclosure can provide the following aspects.
(1) Use of an isoflavone glycoside and/or an isoflavone aglycone and lactobionic acid for producing a skin-improving composition.
(2) Use of glycosides of isoflavones and/or aglycones of isoflavones and lactobionic acid for skin improvement.
(3) Isoflavone glycosides and/or isoflavone aglycones and lactobionic acid for use in skin improvement.
(4) (i) a method of improving skin comprising administering effective amounts of isoflavone glycosides and/or isoflavone aglycones and lactobionic acid to a human in need thereof, or (ii) administering to a human in need of improvement a skin-improving composition, each of which contains an effective amount of an isoflavone-based glycoside and/or an isoflavone-based aglycon and lactobionic acid; how to improve.

Examples are set forth below, but none of the examples are to be construed in a limiting sense.

[Example 1]
<Test contents>
This test was conducted on 33 women aged 30 or older who work at Fujicco Co., Ltd. The subjects were divided into the following three groups.
(a) Placebo group: group taking placebo tablets
(b) Single group: A group ingesting a tablet containing soybean germ extract (powder) (25 mg in aglycone conversion) containing high-purity soybean-derived isoflavone glycosides daidzin, glycitin, and genistin.
(c) Combination group: Soybean germ extract (powder) (25 mg aglycon equivalent) containing high-purity soybean-derived isoflavone glycosides daidzin, glycitin, and genistin, and 250 mg of lactobionic acid. Combination group taking tablets

All of the above tablets were subjected to tableting (300 mg/tablet) with a diameter of 9 mm. The tablets are based on maltodextrin, microcrystalline cellulose, micronized silicon dioxide, calcium stearate. All groups took 3 tablets per day for 12 weeks. Before and 4, 8, and 12 weeks after taking the tablets, the moisture content of the horny skin on the cheeks was measured and evaluated in a single-blind, parallel-group comparison study. The stratum corneum water content was measured by measuring the capacitance of the skin surface using a Corneometer (registered trademark) CM825 (Courage+Khazaka electronic GmbH).

<Preparation of isoflavones>
Soybean germ is extracted with hot water for 40 minutes, solids are removed by filtration, adsorbed on a reversed-phase resin, eluted with ethanol, solids are removed by centrifugation, concentrated, and thermally decomposed. After that, dextrin was added and spray-dried to obtain the soybean germ extract (powder). The total content of isoflavones in the soybean germ extract (powder) was 25%.

<Preparation of lactobionic acid>
(pre-culture)
3 mL of medium containing 0.5% glucose, 0.5% yeast extract, 0.5% polypeptone and 0.1% magnesium sulfate (pH 7.0) was dispensed into a test tube (18 mm x 200 mm) and sterilized at 121°C for 20 minutes. One platinum loop of Gluconobacter cerinus strain NBRC 3267 was inoculated into the medium and cultured overnight at 30°C with shaking (220 rpm). Next, 1 L of the medium having the above composition was dispensed, and the above culture solution was inoculated into a 3 L Erlenmeyer flask sterilized at 121° C. for 20 minutes, followed by shaking culture (220 rpm) at 30° C. for 3 days.

(main culture)
20 L of medium (pH 6.0) containing 1.5% glucose, 0.5% lactose, 0.5% yeast extract, 0.5% polypeptone and 0.1% magnesium sulfate was prepared and sterilized at 121°C for 20 minutes. 1 L of the above preculture solution was inoculated into this, and deep stirring culture (300 rpm, 1 vvm) was carried out at 30°C. After culturing for 48 hours, the cells were collected by centrifugation.

(fermentation)
All the cells obtained in the main culture were suspended in 2 L of medium containing 15% lactose solution and 3% calcium carbonate, and aerated and stirred at 40°C (300 rpm, 1 vvm). After 24 hours, the cells were removed by centrifugation and the supernatant was recovered. The resulting supernatant was spray dried. The resulting dry powder is the lactobionic acid (powder). The content of lactobionic acid in the lactobionic acid (powder) was 51.2%.

<Results>
The results shown in Table 1 were obtained. The numerical values in Table 1 were obtained by subtracting the moisture content of horny corneum on the cheek 12 weeks after intake from the moisture content before intake in each of the single group and the combination group, and the moisture content of horny corneum on the cheek 12 weeks after intake in the placebo group. It is a numerical value obtained by subtracting the value obtained by subtracting the value before ingestion from the
From the results in Table 1, it was confirmed that the combined intake of isoflavone glycosides and lactobionic acid improved the skin.

[Example 2]
<Test content>
This study was a double-blind, placebo-controlled, parallel-group comparative study, and was conducted on 70 healthy adult women aged 30 or older who were concerned about dry skin. The subjects were divided into the following two groups.
(a) Placebo group: group taking placebo tablets
(b) Combination group: Soybean germ extract (powder) (25 mg aglycon equivalent) containing high-purity soybean-derived isoflavone glycosides daidzin, glycitin, and genistin, and 250 mg of lactobionic acid. Combination group taking tablets

All of the above tablets were subjected to tableting (300 mg/tablet) with a diameter of 9 mm. The tablets are based on maltodextrin, microcrystalline cellulose, micronized silicon dioxide, calcium stearate. In both groups, they took one tablet a day (after breakfast) with a glass of water or lukewarm water for 12 weeks. For efficacy evaluation, the subjects visited the hospital every 4 weeks, and skin measurements and other tests were performed. Evaluation items were stratum corneum water content, transepidermal water loss (TEWL), skin viscoelasticity, and skin condition questionnaire.

For skin measurement, after washing the measurement site, the measurement site was exposed, and the specified site was acclimated for 20 minutes or more in a constant temperature and humidity room with a temperature of 20 ± 5 ° C and a humidity of 50 ± 10%. .

The stratum corneum moisture content was measured by measuring the capacitance of the skin surface using Corneometer (registered trademark) CM825 (Courage+Khazaka electronic GmbH). The larger the stratum corneum moisture content, the better.

Transepidermal water loss (TEWL) was measured using a Tewameter® TM300 (Courage+Khazaka electronic GmbH), measuring moisture passing through two sets of highly sensitive temperature and humidity sensors located at the tip of the probe. This was done by measuring the temperature difference and the humidity difference. The lower the transepidermal water loss (TEWL), the better.

Skin viscoelasticity measurements were performed on the left cheek using a Cutometer® MPA580 (Courage+Khazaka electronic GmbH, probe diameter 2 mm). Of the measured values, net elasticity (R5), total body elasticity (R2), and return rate (R7) are values that decrease with aging, and the larger the value, the better. On the other hand, the unrecovered extensibility/retraction capacity (R1) is a value that increases with aging, and the smaller the value, the better.

In the skin condition questionnaire, regarding the skin symptoms in the last 4 weeks at the time of the questionnaire, the skin was worried about pores, the texture was rough, the skin was rough, the spots and freckles were a concern, the complexion was poor, and the skin lacked transparency. , dull skin, dry skin, worrisome wrinkles around the corners of the eyes, sagging under the eyes, lack of firmness and luster, lack of plumpness on the skin, easy to lose makeup, poor makeup application, poor skin condition , oily face, acne-prone skin, and itchy skin (skin itching), subjects answered their subjective symptoms. The subject was trained to objectively evaluate the skin condition questionnaire. As evaluation points, "1 point: I do not think so at all", "2 points: I do not think so much", "3 points: I cannot say either way", "4 points: I somewhat agree", and "5 points: I strongly agree". did. For any item, the smaller the score, the better.

<Results>
Effectiveness analysis between groups in skin measurement and skin condition questionnaire yielded the following results. All the results in the figure are the results when the value before ingestion is set to 0. In the figure, "#" indicates a significant difference between groups (P < 0.05), "##" indicates a significant difference between groups (P < 0.01), and "*" is significant compared to before intake. A difference (P < 0.05) is indicated, and "**" indicates a significant difference (P < 0.01) from before ingestion.
Regarding the moisture content of the stratum corneum (left cheek and left shin), the value of the combination group was higher than that of the placebo group throughout the intake. In particular, it was significantly greater at 4 weeks after ingestion (Fig. 1). In the figure, (a) shows the results for the left cheek, and (b) shows the results for the left shin.
Transepidermal water loss (TEWL) (left shin) was lower in the combination group than in the placebo group throughout the intake period. In particular, it was significantly smaller at 4 weeks after ingestion (Fig. 2).
Skin viscoelasticity (left cheek) net elasticity (R5), total body elasticity (R2), and rate of rebound (R7) were greater in the combination group than in the placebo group throughout intake. In particular, it was significantly greater at 8 and 12 weeks after ingestion. Regarding the unrecovered extensibility/retraction ability (R1) of skin viscoelasticity (left cheek), values were lower in the combination group than in the placebo group throughout the intake. In particular, it was significantly smaller at 8 weeks and 12 weeks after ingestion (Figs. 3 and 4). In FIG. 3, (a) shows the net elasticity (R5), and (b) shows the total body elasticity (R2). In FIG. 4, (a) shows the return rate (R7), and (b) shows the unrecovered extensibility/retraction capacity (R1).
In the skin condition questionnaire, the combination group scored lower than the placebo group for "sagging under the eyes" throughout the intake. Especially, it was significantly smaller at 8 weeks and 12 weeks after ingestion (Fig. 5).

Claims (2)

Containing isoflavone glycosides and/or isoflavone aglycones and lactobionic acid ,
The total daily intake of the isoflavone glycosides and/or isoflavone aglycones is 20 mg or more and less than 30 mg in terms of aglycone, and the daily intake of the lactobionic acid is 200 mg or more . Composition for skin improvement. The composition according to claim 1 , which is a food or drink.

Images